Literature DB >> 7678220

Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids.

L A Krummen1, T K Woodruff, G DeGuzman, E T Cox, D L Baly, E Mann, S Garg, W L Wong, P Cossum, J P Mather.   

Abstract

Inhibins and activins are produced by a variety of tissues and may have important endocrine and paracrine roles in development, reproduction, and hematopoiesis. However, little is known regarding the physical properties or concentrations of inhibin and activin in biological fluids. Binding proteins for inhibin or activin in serum or at production or target sites may have important implications for restricting the bioactivity of these hormones and may alter the immunoreactivity of these molecules in biological fluids. The objective of this study was to identify inhibin- and activin-binding proteins in human serum (HS) and follicular fluid (hFF) and determine the ability of these proteins to alter biological or immunological activity. In HS, [125I]activin and inhibin bound to a protein identified as alpha 2-macroglobulin (alpha 2M) using three criteria: 1) [125I]inhibin and activin bind purified alpha 2M, but not several other serum proteins tested; 2) complexes formed by [125I]inhibin and activin in HS and in the presence of purified alpha 2M elute with similar retention times on HPLC; and 3) preadsorption of HS with alpha 2M antiserum inhibits inhibin and activin binding to this protein while antiserum directed against follistatin or other serum proteins had no effect. A small amount of a lower mol wt [125I]activin-follistatin complex was also found in HS. This complex eluted with a retention time similar to that of activin bound to purified porcine follistatin. Binding of inhibin to follistatin could not be detected in HS. In contrast, follistatin was the major binding protein of both activin and inhibin in hFF. Concentrations up to 100 micrograms/ml purified alpha 2M had no effect on the bioactivity or immunoreactivity of either inhibin or activin. In contrast, follistatin inhibited both activin-stimulated pituitary FSH release and K562 hemoglobin production as well as antiserum binding in a specific activin-A immunoassay. Follistatin did not interfere with inhibin immunodetection. These data indicate that two inhibin- and activin-binding proteins are present in different relative amounts in HS and hFF, alpha 2M, the primary binding protein in HS, did not alter inhibin or activin bio- or immunoactivity under the conditions of these experiments, while follistatin, the major binding protein in hFF, may mask activin's bio- and immunoactivities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678220     DOI: 10.1210/endo.132.1.7678220

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

Review 1.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

2.  Transforming growth factor beta-activated kinase 1 is a key mediator of ovine follicle-stimulating hormone beta-subunit expression.

Authors:  Nedal Safwat; Jun Ninomiya-Tsuji; A Jesse Gore; William L Miller
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

3.  Identification of biologically active inhibin in the peritoneal fluid of women.

Authors:  R B Billiar; R Hemmings; P Smith; N Groome
Journal:  J Assist Reprod Genet       Date:  1995-01       Impact factor: 3.412

4.  Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass.

Authors:  Brian C Goh; Vandana Singhal; Angelica J Herrera; Ryan E Tomlinson; Soohyun Kim; Marie-Claude Faugere; Emily L Germain-Lee; Thomas L Clemens; Se-Jin Lee; Douglas J DiGirolamo
Journal:  J Biol Chem       Date:  2017-06-28       Impact factor: 5.157

5.  Virtual High-Throughput Screening To Identify Novel Activin Antagonists.

Authors:  Jie Zhu; Rama K Mishra; Gary E Schiltz; Yogeshwar Makanji; Karl A Scheidt; Andrew P Mazar; Teresa K Woodruff
Journal:  J Med Chem       Date:  2015-07-07       Impact factor: 7.446

6.  Interleukin-1 beta enhances and interferon-gamma suppresses activin A actions by reciprocally regulating activin A and follistatin secretion from bone marrow stromal fibroblasts.

Authors:  M Abe; Y Shintani; Y Eto; K Harada; Y Fujinaka; M Kosaka; T Matsumoto
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

7.  Activin signaling: effects on body composition and mitochondrial energy metabolism.

Authors:  Liunan Li; Joseph J Shen; Juan C Bournat; Lihua Huang; Abanti Chattopadhyay; Zhihong Li; Chad Shaw; Brett H Graham; Chester W Brown
Journal:  Endocrinology       Date:  2009-04-23       Impact factor: 4.736

8.  Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators.

Authors:  Tatyana A Souza; Xuan Chen; Yongjing Guo; Parid Sava; Jimin Zhang; Jennifer J Hill; Paul J Yaworsky; Yongchang Qiu
Journal:  Mol Endocrinol       Date:  2008-10-16

9.  The bidirectional transfer and fetal vascular pressure changes due to the presence of 125I-labeled inhibin A in the ex-vivo human placental model.

Authors:  Roger E Bawdon; Victor Ghetie
Journal:  Infect Dis Obstet Gynecol       Date:  2003
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.